Department of Orthopaedics, Duke University Medical Center, Durham, NC 27710, USA.
Clin Orthop Relat Res. 2013 Jul;471(7):2206-11. doi: 10.1007/s11999-012-2781-x. Epub 2013 Jan 16.
Avascular necrosis (AVN) of the femoral head is a potential complication in patients with slipped capital femoral epiphysis (SCFE), radiographically occurring in 3-60%. This may lead to early hip fusion or hip arthroplasty. Free vascularized fibular grafting (FVFG) may provide a reasonable means to preserve the femoral head.
QUESTIONS/PURPOSES: We asked: (1) What percentage of patients with AVN after SCFE treated with FVFG underwent subsequent THA or hip fusion and what was the lifespan of the FVFG? (2) Did the graft survival rate of FVFG for AVN after SCFE coincide with historically reported rates of FVFG for idiopathic AVN? And (3) did hip function improve after FVFG?
We retrospectively reviewed 52 patients who underwent FVFG for SCFE. We calculated the longevity of the graft and factors associated with graft survival. Harris hip scores (HHS) were recorded pre- and postoperatively. Minimum followup was 1 month (median, 19 months; range, 1-136 months).
Five of the 52 patients (10%) underwent conversion to THA (four) or hip fusion (one). Mean age was greater in these patients than in those not requiring further procedures: 16 versus 13 years. Median graft survival time before arthroplasty/fusion was 12 years (range, 2-16 years) while it is currently 8 years (range, 2-16 years) in patients not undergoing subsequent procedures. HHSs improved 35 points on average (38 points preoperatively to 73 points postoperatively).
In patients undergoing FVFG for AVN secondary to SCFE, 90% have maintained their native hips for 8 years with improved hip function, similar to other published reports of FVFG. Further followup is needed of patients currently retaining their FVFGs as to eventual conversion to THA or fusion.
Level IV, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.
股骨头缺血性坏死(AVN)是骺滑脱(SCFE)患者的潜在并发症,放射学发生率为 3-60%。这可能导致早期髋关节融合或髋关节置换。游离血管化腓骨移植(FVFG)可能是保留股骨头的合理手段。
问题/目的:我们提出了以下问题:(1)接受 FVFG 治疗的 SCFE 后发生 AVN 的患者中有多少例随后接受了 THA 或髋关节融合,FVFG 的寿命是多少?(2)FVFG 治疗 SCFE 后 AVN 的移植物存活率是否与 FVFG 治疗特发性 AVN 的历史报告率相符?(3)FVFG 后髋关节功能是否改善?
我们回顾性分析了 52 例接受 FVFG 治疗的 SCFE 患者。我们计算了移植物的寿命和与移植物存活相关的因素。记录术前和术后的 Harris 髋关节评分(HHS)。随访时间至少为 1 个月(中位数 19 个月;范围 1-136 个月)。
52 例患者中有 5 例(10%)需要进行关节置换(4 例)或髋关节融合(1 例)。需要进一步手术的患者年龄大于不需要进一步手术的患者:16 岁对 13 岁。在需要进行关节置换/融合之前,移植物的中位存活时间为 12 年(范围 2-16 年),而目前未进行进一步手术的患者的移植物存活时间为 8 年(范围 2-16 年)。HHS 平均提高了 35 分(术前 38 分,术后 73 分)。
在接受 FVFG 治疗 SCFE 继发 AVN 的患者中,90%的患者在 8 年内保持了自己的髋关节,髋关节功能得到了改善,这与其他发表的 FVFG 报告相似。需要进一步随访目前保留 FVFG 的患者,以了解他们最终是否需要进行 THA 或融合。
IV 级,治疗性研究。请参阅作者说明,以获取完整的证据水平描述。